SCHEMBL1827339

SCHEMBL1827339

CCOC(=O)C(CNC(=O)OC(C)(C)C)c1ccc(OS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.43
ATM Q13315 1/20 0.42
EGFR P00533 1/20 0.42
P2RX7 Q99572 8/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MMP13 P45452 1/20 0.40
RAB9A P51151 2/20 0.39
NPC1 O15118 1/20 0.39
ADAMTS4 O75173 1/20 0.39
CA12 O43570 2/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
PPARG P37231 1/20 0.38
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827842 0.93 EGFR (0.43) SYKEGFRP2RX7SMN1; SMN2ALDH1A1
SCHEMBL1825461 0.92 EGFR (0.44) EGFRP2RX7ALDH1A1CA12CA1
SCHEMBL1824701 0.92 EGFR (0.43) SYKEGFRP2RX7SMN1; SMN2ALDH1A1
SCHEMBL1823128 0.90 SYK (0.51) SYKEGFRP2RX7MMP13CA12
SCHEMBL1826055 0.89 SYK (0.41) SYKATMEGFRP2RX7SMN1; SMN2
SCHEMBL1825264 0.89 MMP13 (0.41) SYKEGFRP2RX7SMN1; SMN2ALDH1A1
SCHEMBL3574127 0.87 P2RX7 (0.55) SYKEGFRP2RX7
SCHEMBL1823821 0.86 SYK (0.42) SYKEGFRSMN1; SMN2CA12CA1
SCHEMBL1824335 0.86 SMN1; SMN2 (0.44) ATMSMN1; SMN2ALDH1A1RAB9ANPC1
SCHEMBL1825827 0.86 HSD17B10 (0.45) SYKP2RX7SMN1; SMN2ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 SYK 1520/4885ATM 4601/4885EGFR 1025/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 SYK 1172/4885ATM 4386/4885EGFR 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.